Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Romine, J. S.
  • Sipe, J. C.
  • Koziol, James
  • Zyroff, J.
  • Beutler, Ernest

publication date

  • January 1999

journal

  • Proceedings of the Association of American Physicians  Journal

abstract

  • We conducted an 18-month, placebo-controlled, double-blind study to evaluate cladribine in the treatment of 52 patients with relapsing-remitting multiple sclerosis. Patients received either placebo or cladribine 0.07 mg/kg/day by subcutaneous injection for 5 consecutive days as six monthly courses for a total cumulative dose of 2.1 mg/kg. Analysis of results revealed a statistically significant favorable effect of cladribine on the joint frequency and severity of relapses and magnetic resonance imaging (MRI) findings. MRI-enhancing lesions were completely suppressed in the cladribine patients by the sixth month of treatment. Mild segmental herpes zoster occurred in two cladribine-treated patients and one patient receiving placebo. Otherwise, there were no side effects or adverse events. We conclude that cladribine shows promise as a treatment for relapsing-remitting multiple sclerosis.

subject areas

  • Administration, Cutaneous
  • Adult
  • Cladribine
  • Double-Blind Method
  • Female
  • Humans
  • Immunosuppressive Agents
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Multiple Sclerosis
  • Recurrence
  • Treatment Outcome
scroll to property group menus

Research

keywords

  • 2-chlorodeoxyadenosine
  • immunosuppression
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1081-650X

Digital Object Identifier (DOI)

  • 10.1046/j.1525-1381.1999.09115.x

PubMed ID

  • 9893155
scroll to property group menus

Additional Document Info

start page

  • 35

end page

  • 44

volume

  • 111

issue

  • 1

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support